乳腺癌中的酪氨酸激酶信号传导：表皮生长因子受体（ErbB）家族受体酪氨酸激酶
Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases.
作者信息
Stern D F
机构信息
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520-8023, USA.
出版信息
Breast Cancer Res. 2000;2(3):176-83. doi: 10.1186/bcr51. Epub 2000 Mar 25.
Abstract
ERBB family receptor tyrosine kinases are overexpressed in a significant subset of breast cancers. One of these receptors, HER2/neu, or ErbB-2, is the target for a new rational therapeutic antibody, Herceptin. Other inhibitors that target this receptor, and another family member, the epidermal growth factor (EGF) receptor, are moving into clinical trials. Both of these receptors are sometimes overexpressed in breast cancer, and still subject to regulation by hormones and other physiological regulators. Optimal use of therapeutics targeting these receptors will require consideration of the several modes of regulation of these receptors and their interactions with steroid receptors.
摘要
ERBB家族受体酪氨酸激酶在相当一部分乳腺癌中过度表达。这些受体之一，HER2/neu，即ErbB-2，是一种新型合理治疗性抗体赫赛汀的靶点。其他靶向该受体以及另一个家族成员表皮生长因子（EGF）受体的抑制剂正在进入临床试验阶段。这两种受体在乳腺癌中有时都会过度表达，并且仍然受到激素和其他生理调节因子的调控。要想最佳地使用针对这些受体的治疗方法，就需要考虑这些受体的多种调控模式以及它们与类固醇受体的相互作用。
相似文献
1
Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases.乳腺癌中的酪氨酸激酶信号传导：表皮生长因子受体（ErbB）家族受体酪氨酸激酶
Breast Cancer Res. 2000;2(3):176-83. doi: 10.1186/bcr51. Epub 2000 Mar 25.
2
The role of overexpressed HER2 in transformation.过表达的HER2在转化过程中的作用。
Ann Oncol. 2001;12 Suppl 1:S9-13. doi: 10.1093/annonc/12.suppl_1.s9.
3
HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer.人表皮生长因子受体（erbB）酪氨酸激酶抑制剂在乳腺癌治疗中的应用
Semin Oncol. 2002 Jun;29(3 Suppl 11):4-10. doi: 10.1053/sonc.2002.34047.
4
Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.表皮生长因子受体共表达通过特定的erbB受体相互作用和激活来调节HER2/neu过表达乳腺癌细胞对赫赛汀的敏感性。
Exp Cell Res. 2005 Apr 1;304(2):604-19. doi: 10.1016/j.yexcr.2004.12.008. Epub 2005 Jan 21.
5
Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.HER4 的存在与转移性乳腺癌患者对赫赛汀的敏感性增加有关。
Breast Cancer Res. 2009;11(4):R50. doi: 10.1186/bcr2339. Epub 2009 Jul 22.
6
HER2 targeted therapy in breast cancer...beyond Herceptin.乳腺癌中的HER2靶向治疗……超越赫赛汀。
Rev Endocr Metab Disord. 2007 Sep;8(3):269-77. doi: 10.1007/s11154-007-9040-6.
7
Targeting HER2: recent developments and future directions for breast cancer patients.靶向人表皮生长因子受体2：乳腺癌患者的最新进展与未来方向
Semin Oncol. 2001 Dec;28(6 Suppl 18):21-9. doi: 10.1053/sonc.2001.29724.
8
Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities.表皮生长因子相关肽激活不同的ErbB受体亚群，且它们的生物学活性存在差异。
J Biol Chem. 1996 Mar 15;271(11):6071-6. doi: 10.1074/jbc.271.11.6071.
9
Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment.Her-2/neu引发的细胞内酪氨酸激酶激活：非配体依赖性激活机制的体内相关性及其对基于曲妥珠单抗治疗疗效的影响
Br J Cancer. 2003 Sep 15;89(6):983-91. doi: 10.1038/sj.bjc.6601160.
10
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.在体内对曲妥珠单抗产生耐药性的人乳腺癌细胞过表达表皮生长因子受体和ErbB配体，并且仍然依赖于ErbB受体网络。
Clin Cancer Res. 2007 Aug 15;13(16):4909-19. doi: 10.1158/1078-0432.CCR-07-0701.
引用本文的文献
1
Phosphatidylinositol 4,5-bisphosphate drives the formation of EGFR and EphA2 complexes.磷脂酰肌醇-4,5-二磷酸驱动表皮生长因子受体（EGFR）和红细胞生成素产生肝细胞受体A2（EphA2）复合物的形成。
Sci Adv. 2024 Dec 6;10(49):eadl0649. doi: 10.1126/sciadv.adl0649. Epub 2024 Dec 4.
2
Sprouty genes regulate activated fibroblasts in mammary epithelial development and breast cancer.芽基基因调节乳腺上皮发育和乳腺癌中的激活成纤维细胞。
Cell Death Dis. 2024 Apr 10;15(4):256. doi: 10.1038/s41419-024-06637-2.
3
Anticancer potential of novel symmetrical and asymmetrical dihydropyridines against breast cancer EGFR inhibition: molecular design, synthesis, analysis and screening.新型对称和不对称二氢吡啶对乳腺癌的抗癌潜力：表皮生长因子受体抑制作用——分子设计、合成、分析及筛选
RSC Adv. 2024 Apr 9;14(16):11368-11387. doi: 10.1039/d4ra01424c. eCollection 2024 Apr 3.
4
Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies.内体回收抑制剂下调雌激素受体-α并与内分泌治疗协同作用。
Breast Cancer Res Treat. 2024 Apr;204(3):631-642. doi: 10.1007/s10549-023-07225-2. Epub 2024 Jan 16.
5
A Unified Bayesian Framework for Bi-overlapping-Clustering Multi-omics Data via Sparse Matrix Factorization.一种通过稀疏矩阵分解实现双重叠聚类多组学数据的统一贝叶斯框架。
Stat Biosci. 2023 Dec;15(3):669-691. doi: 10.1007/s12561-022-09350-w. Epub 2022 Jul 8.
6
Biased activation of the receptor tyrosine kinase HER2.受体酪氨酸激酶 HER2 的偏激活。
Cell Mol Life Sci. 2023 May 20;80(6):158. doi: 10.1007/s00018-023-04806-8.
7
Embryonic Programs in Cancer and Metastasis-Insights From the Mammary Gland.癌症与转移中的胚胎程序——来自乳腺的见解
Front Cell Dev Biol. 2022 Jun 29;10:938625. doi: 10.3389/fcell.2022.938625. eCollection 2022.
8
Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review.ErbB1 在拉帕替尼引起腹泻的潜在机制中的作用：综述。
Biomed Res Int. 2022 Jun 28;2022:4165808. doi: 10.1155/2022/4165808. eCollection 2022.
9
Recombinant immunotoxins development for HER2-based targeted cancer therapies.用于基于HER2的靶向癌症治疗的重组免疫毒素研发。
Cancer Cell Int. 2021 Sep 6;21(1):470. doi: 10.1186/s12935-021-02182-6.
10
Tumour-specific Causal Inference Discovers Distinct Disease Mechanisms Underlying Cancer Subtypes.肿瘤特异性因果推理发现癌症亚型潜在的不同疾病机制。
Sci Rep. 2019 Sep 13;9(1):13225. doi: 10.1038/s41598-019-48318-7.
本文引用的文献
1
Tyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer.乳腺癌中的酪氨酸激酶信号传导：人乳腺癌转基因小鼠模型中的酪氨酸激酶介导的信号转导
Breast Cancer Res. 2000;2(3):211-6. doi: 10.1186/bcr56. Epub 2000 Apr 12.
2
Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors.乳腺癌中的酪氨酸激酶信号传导：成纤维细胞生长因子及其受体
Breast Cancer Res. 2000;2(3):191-6. doi: 10.1186/bcr53. Epub 2000 Mar 25.
3
Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification.乳腺癌中的酪氨酸激酶信号传导。表皮生长因子受体：信号整合与多样化的汇聚点。
Breast Cancer Res. 2000;2(3):184-90. doi: 10.1186/bcr52. Epub 2000 Mar 25.
4
Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.ErbB-2（HER-2/neu）的激活（酪氨酸磷酸化）：一项关于乳腺癌发病率及其与预后相关性的研究
J Clin Oncol. 2000 Sep 15;18(18):3230-9. doi: 10.1200/JCO.2000.18.18.3230.
5
Transcriptional regulation of type I receptor tyrosine kinases in the mammary gland.乳腺中I型受体酪氨酸激酶的转录调控
J Mammary Gland Biol Neoplasia. 1997 Apr;2(2):153-63. doi: 10.1023/a:1026303814855.
6
ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation.乳腺中的ErbB4信号传导是泌乳期间小叶腺泡发育和Stat5激活所必需的。
J Cell Biol. 1999 Oct 4;147(1):77-88. doi: 10.1083/jcb.147.1.77.
7
Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.表皮生长因子受体（ErbB）的可控二聚化作用为同型二聚体和异型二聚体的差异信号传导提供了证据。
Mol Cell Biol. 1999 Oct;19(10):6845-57. doi: 10.1128/MCB.19.10.6845.
8
The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor.HER-2/neu受体酪氨酸激酶基因编码一种分泌型自抑制剂。
Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10869-74. doi: 10.1073/pnas.96.19.10869.
9
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).针对曲妥珠单抗（赫赛汀）作用机制的非临床研究。
Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70.
10
Genome-wide analysis of DNA copy-number changes using cDNA microarrays.利用cDNA微阵列对DNA拷贝数变化进行全基因组分析。
Nat Genet. 1999 Sep;23(1):41-6. doi: 10.1038/12640.
Zotero 插件